English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

For most solid tumors, including melanoma, the most powerful predictor of recurrence and survival is the presence or absence of regional lymph node metastases. For patients with melanoma and stage III disease, the five-year survival decreases 40% compared to patients without nodal metastases. With the approval of interferon alfa-2b as the first effective adjuvant therapy for the high risk for recurrence melanoma population, one can argue that patients with a defined rate of nodal metastases (tumor thickness >1 mm) should have a nodal staging procedure as part of their primary therapy. Lymphatic mapping with sentinel lymph node (SLN) biopsy is the least morbid method to obtain this information.

Malignant Melanoma: Staging and Treatment of Localized and Advanced Disease